STEER was a retrospective, observational real-world study, evaluating the efficacy of Wegovy (semaglutide) 2.4 mg versus tirzepatide in lowering the risk of MACE in US adults with overweight or obesity and established CVD with no prior history of diabetes, with a primary outcome measure of revised 5-point MACE (heart attack, stroke, hospitalization for heart failure, coronary revascularization, and death from any cause) and revised 3-point MACE (heart attack, stroke and death from any cause)
Results The matched analytic sample consisted of 66,574 encounters when SGAs with 56% low, 35% intermediate, and 8% expected AIWG were prescribed, of which 13,319 involved prescription of semaglutide or tirzepatide (Table 1)
Alternatively, in the absence of ACMSD activity, ACMS can spontaneously decay into quinolinic acid, a biosynthetic precursor to NAD + (see Fig
Liu P, Chen G, Zhang J
Here, the Improving Diabetes Steering Committee provides practical advice on the use of SGLT2i treatment in four major groups of people with T2DM: people with established CVD, people at high risk for developing CVD, people at lower risk of developing CVD and frail people
in my mid-20s, I would hobble to the trash chute and hide them in that room